Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T
Exclusive reporting reveals a third death in China's opaque gene therapy trials, sparking intense scrutiny of safety oversight.
11 trends tracked about this subject — the full history, oldest to newest below.
Exclusive reporting reveals a third death in China's opaque gene therapy trials, sparking intense scrutiny of safety oversight.
The death of a child in a gene editing trial exposes the ethical perils and limits of scientific advancement.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Personalized gene therapy using bespoke ASOs has enabled a teen with SCN2A-related epileptic encephalopathy to walk independently for the first time.
A $160 million non-profit initiative in Boston aims to revolutionize the development of genetic medicines for rare and ultra-rare diseases.
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Researchers have initiated the first human clinical trial focused on reversing cellular aging through experimental gene therapy.
The FDA is allowing Regenxbio to resubmit its gene therapy for Hunter syndrome, marking a reversal of a previous rejection.
A lupus treatment borrowed from cancer therapy is putting patients into remission—with one calling it life-changing.
The gene editing landscape is expanding rapidly through next-generation CRISPR tools and significant projected market growth through 2028.